MBX 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

MBX ▼ -13.43% at T+20d

LONG call ✗ call lost -13.43% · α vs SPY -16.56% · entry $34.71 → $30.05

Next anchor: T+60d in 7w

Currently $35.51 · +2.30% from $34.71 entry

Entry anchored
May 7, 10:33 AM ET
via Databento tick

T+1d

+18.02%

call +18.02% · α +17.19%

$40.97

settled 5w ago

T+5d

+8.04%

call +8.04% · α +6.53%

$37.50

settled 4w ago

T+20d

-13.43%

call -13.43% · α -16.56%

$30.05

settled 8d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

MBX Biosciences reported Q1 2026 results with an EPS of -$0.50, beating consensus of -$0.62 by 19.4%. Net loss narrowed slightly to $23.5M from $23.9M a year ago, while cash position strengthened to $440M providing runway into 2029. Pipeline milestones remain on track, including Phase 3 initiation for canvuparatide in Q3 2026 and obesity data events.

Actionable Insight

The EPS beat and strong cash position are positive, but the stock will likely trade on pipeline catalysts. Watch obesity day (May 11) for initial MBX 4291 data and ENDO presentation (June) for full canvuparatide Phase 2 results.

Key Facts

EPS of -$0.50 beat consensus of -$0.62 by 19.4%
Cash and investments of $440.0M, up from $373.7M at Dec 2025
Net loss of $23.5M improved slightly vs $23.9M in Q1 2025
Phase 3 trial of canvuparatide on track to initiate in Q3 2026
Obesity Day on May 11 with initial blinded Phase 1 data for MBX 4291
Phase 2 Avail results for canvuparatide accepted for oral presentation at ENDO June 2026

Financial Impact

EPS beat of ~$0.12 (19.4%) vs consensus, but no revenue stream to impact

epscash positionnet loss

Risk Factors

Clinical trial failures for lead programs (canvuparatide, MBX 4291)
Cash burn rate may accelerate with Phase 3 initiation
No approved products or revenue

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

87% bullish (15 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-210825
Document: mbx-20260507.htm	0001193125-26-210825
Document: 0001193125-26-210825-index-headers.html	0001193125-26-210825
Document: 0001193125-26-210825-index.html	0001193125-26-210825
Document: 0001193125-26-210825.txt	0001193125-26-210825
8-K Data (Synthetic)	0001193125-26-210825

22 reports for MBX

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+5▲ +22.70%May 11, 2026

Filters

Reports for MBX — sortable, filterable
	Type				Now
Jun 12, 2026 1d ago	8-K BULLISH ★ 7/10	$35.51 awaiting T+5	awaiting T+5	—	$35.51 (−0.00%)
Jun 12, 2026 1d ago	Press Release BULLISH ★ 6/10	$35.51 awaiting T+5	awaiting T+5	—	$35.51 (−0.00%)
Jun 11, 2026 1d ago	Institutional Cluster BULLISH ★ 5/10	$33.21 awaiting T+5	awaiting T+5	—	$35.51 (+6.93%)
Jun 11, 2026 2d ago	Institutional Cluster NEUTRAL ★ 3/10	$31.79 awaiting T+5	awaiting T+5	—	$35.51 (+11.70%)
Jun 10, 2026 2d ago	144 NEUTRAL ★ 2/10	$29.91 awaiting T+5	awaiting T+5	—	$35.51 (+18.72%)
Jun 9, 2026 3d ago	144 BEARISH ★ 5/10	$29.80 awaiting T+5	awaiting T+5	—	$35.51 (−19.16%)
Jun 5, 2026 8d ago	8-K NEUTRAL ★ 3/10	$30.59 awaiting T+5	awaiting T+5	—	$35.51 (+16.08%)
May 11, 2026 4w ago	144 BEARISH ★ 5/10	$40.08 $30.98	▲ +22.70%	▲ +22.62%	$35.51 (+11.40%)
May 11, 2026 4w ago	Press Release MIXED ★ 6/10	$40.08 $30.98	▼ −22.70%	▼ −22.62%	$35.51 (−11.40%)
May 8, 2026 5w ago	144 NEUTRAL ★ 3/10	$40.97 $35.36	▼ −13.68%	▼ −15.15%	$35.51 (−13.32%)

US Market Status

Market Closed — Opens Mon (49h 35m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access